IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production

Blood

Volumn 115, Issue 23, 2010, Pages 4699-4706

  Maeda, Kenichiro ^a   Mehta, Harshini ^a,b   Drevets, Douglas A ^c   Coggeshall, K Mark ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; INOSITOL 1,4,5 TRISPHOSPHATE 5 PHOSPHATASE; INOSITOL-1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; INTERLEUKIN 6; PHOSPHATASE;

AGING; ANIMAL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CELL CULTURE; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; MOUSE MUTANT; MYELOPOIESIS; PERITONEUM MACROPHAGE;

AGING; ANIMALS; ANTIBODY FORMATION; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD45; B-LYMPHOCYTES; CELLS, CULTURED; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES, PERITONEAL; MICE; MICE, KNOCKOUT; MYELOPOIESIS; PHOSPHORIC MONOESTER HYDROLASES; RECEPTORS, IGG;

EID: 77954733595     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-230631     Document Type: Article

References (70)

1. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol. 2005;23:1-21. (Pubitemid 40563163)
2. Yoshizaki K, Nakagawa T, Fukunaga K, Tseng LT, Yamamura Y, Kishimoto T. Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol. 1984;132(6):2948-2954.
3. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989;86(19):7547-7551.
4. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;27(5):461-466. (Pubitemid 47319257)
5. Knudsen LS, Klarlund M, Skjodt H, et al. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis: relationship to disease activity and radiographic outcome. J Rheumatol. 2008;35(7):1277-1287.
6. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332(6159):83-85.
7. Atsumi T, Ishihara K, Kamimura D, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002;196(7):979-990.
8. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119(3):296-305. (Pubitemid 44571047)
9. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004;13(5):339-343. (Pubitemid 38788493)
10. Neng Lai K, Leung JC, Bik Lai K, Li PK, Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J Pathol. 1996;178(4):451-457.
11. Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2003;62(1):37-42. (Pubitemid 36005793)
12. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol. 1993;151(11):6525-6534.
13. Oak JS, Fruman DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity. 2007;40(6):433-441.
14. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis PC, Hawkins PT. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell. 1994;77(1):83-93. (Pubitemid 24184690)
15. Fruman DA. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol. 2004;16(3):314-320.
16. Ruse M, Knaus UG. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol Res. 2006;34(1):33-48.
17. Park SY, Ueda S, Ohno H, et al. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J Clin Invest. 1998;102(6):1229-1238.
18. Cooney DS, Phee H, Jacob A, Coggeshall KM. Signal transduction by human-restricted Fc gamma RIIa involves three distinct cytoplasmic kinase families leading to phagocytosis. J Immunol. 2001;167(2):844-854. (Pubitemid 32660840)
19. Ganesan LP, Joshi T, Fang H, et al. FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood. 2006;108(2):718-725.
20. Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003;4(4):313-319.
21. Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med. 2005;11(9):933-935.
22. Camps M, Ruckle T, Ji H, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005;11(9):936-943.
23. Firestein GS. Inhibiting inflammation in rheumatoid arthritis. N Engl J Med. 2006;354(1):80-82.
24. Maresco DL, Osborne JM, Cooney D, Coggeshall KM, Anderson CL. The SH2-containing 5′-inositol phosphatase (SHIP) is tyrosine phosphorylated after Fc gamma receptor clustering in monocytes. J Immunol. 1999;162(11):6458- 6465. (Pubitemid 29309367)
25. Nakamura K, Malykhin A, Coggeshall KM. The Src homology 2 domain-containing inositol 5-phosphatase negatively regulates Fcgamma receptor-mediated phagocytosis through immunoreceptor tyrosine-based activation motifbearing phagocytic receptors. Blood. 2002;100(9):3374-3382.
26. Huber M, Helgason CD, Damen JE, Liu L, Humphries RK, Krystal G. The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci U S A. 1998;95(19):11330-11335.
27. Brauweiler A, Tamir I, Dal Porto J, et al. Differential regulation of B cell development, activation, and death by the src homology 2 domaincontaining 5′ inositol phosphatase (SHIP). J Exp Med. 2000;191(9):1545-1554.
28. Nakamura K, Kouro T, Kincade PW, Malykhin A, Maeda K, Coggeshall KM. Src homology 2-containing 5-inositol phosphatase (SHIP) suppresses an early stage of lymphoid cell development through elevated interleukin-6 production by myeloid cells in bone marrow. J Exp Med. 2004;199(2):243-254. (Pubitemid 38129704)
29. Maeda K, Baba Y, Nagai Y, et al. IL-6 blocks a discrete early step in lymphopoiesis. Blood. 2005;106(3):879-885.
30. Helgason CD, Damen JE, Rosten P, et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998;12(11):1610-1620. (Pubitemid 28299513)
31. Helgason CD, Kalberer CP, Damen JE, et al. A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of B lymphocytes in ship -/- mice. J Exp Med. 2000;191(5):781-794.
32. Vedham V, Phee H, Coggeshall KM. Vav activation and function as a Rac guanine nucleotide exchange factor in macrophage colony-stimulating factor-induced macrophage chemotaxis. Mol Cell Biol. 2005;25(10):4211-4220.
33. Rauh MJ, Kalesnikoff J, Hughes M, Sly L, Lam V, Krystal G. Role of Src homology 2-containing-inositol 5′-phosphatase (SHIP) in mast cells and macrophages. Biochem Soc Trans. 2003;31(1):286-291.
34. Rauh MJ, Ho V, Pereira C, et al. SHIP represses the generation of alternatively activated macrophages. Immunity. 2005;23(4):361-374.
35. Kuroda E, Ho V, Ruschmann J, et al. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J Immunol. 2009;183(6):3652-3660.
36. Xu Y, Wiernik PH. Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus. 2001;10(12):841-850. (Pubitemid 34016862)
37. Moody JL, Pereira CG, Magil A, Fritzler MJ, Jirik FR. Loss of a single allele of SHIP exacerbates the immunopathology of Pten heterozygous mice. Genes Immun. 2003;4(1):60-66.
38. Takeshita S, Namba N, Zhao JJ, et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med. 2002;8(9):943-949.
39. Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM. Interleukin 6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosisprone B6.Sle1.Yaa animals. Blood. 2009;113(19):4534-4540.
40. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR γ-chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76(3):519-529. (Pubitemid 24064172)
41. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991;350(6317):423-426.
42. Ganesan LP, Wei G, Pengal RA, et al. The serine/threonine kinase Akt promotes Fc gamma receptor-mediated phagocytosis in murine macrophages through the activation of p70S6 kinase. J Biol Chem. 2004;279(52):54416-54425.
43. Sunderkötter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol. 2004;172(7):4410-4417. (Pubitemid 38375256)
44. DaMatta RA, Araujo-Jorge T, de Souza W. Subpopulations of mouse resident peritoneal macrophages fractionated on Percoll gradients show differences in cell size, lectin binding and antigen expression suggestive of different stages of maturation. Tissue Cell. 1995;27(5):505-513.
45. Mehta H, Glogauer M, Becart S, Altman A, Coggeshall KM. Adaptor protein SLAT modulates Fcgamma receptor-mediated phagocytosis in murine macrophages. J Biol Chem. 2009;284(18):11882-11891.
46. Rose DM, Winston BW, Chan ED, et al. Fc gamma receptor cross-linking activates p42, p38, and JNK/SAPK mitogen-activated protein kinases in murine macrophages: role for p42MAPK in Fc gamma receptor-stimulated TNF-alpha synthesis. J Immunol. 1997;158(7):3433-3438.
47. Utomo A, Cullere X, Glogauer M, Swat W, Mayadas TN. Vav proteins in neutrophils are required for FcgammaR-mediated signaling to Rac GTPases and nicotinamide adenine dinucleotide phosphate oxidase component p40(phox). J Immunol. 2006;177(9):6388-6397.
48. Alarcón-Riquelme ME, Moller G, Fernandez C. Macrophage depletion decreases IgG anti-DNA in cultures from (NZB x NZW)F1 spleen cells by eliminating the main source of IL-6. Clin Exp Immunol. 1993;91(2):220-225. (Pubitemid 23045665)
49. Kim CH, Hangoc G, Cooper S, et al. Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest. 1999;104(12):1751-1759.
50. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity. 2004;21(2):227-239. (Pubitemid 39094052)
51. Schett G. Immune cells and mediators of inflammatory arthritis [review]. Autoimmunity. 2008;41(3):224-229.
52. Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum. 2010;39(6):491-503.
53. Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol. 2008;20(5):538-544.
54. Tosato G, Seamon KB, Goldman ND, et al. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science. 1988;239(4839):502-504.
55. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002;169(8):4213-4221. (Pubitemid 35178192)
56. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339-342.
57. Katsume A, Miyai T, Suzuki H, et al. Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol. 1997;82(2):117-124.
58. Duits AJ, Aarden LA, Ernst LK, Capel PJ, van de Winkel JG. Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6. Clin Exp Immunol. 1993;92(2):225-231.
59. Chacko GW, Duchemin AM, Coggeshall KM, Osborne JM, Brandt JT, Anderson CL. Clustering of the platelet Fc gamma receptor induces noncovalent association with the tyrosine kinase p72syk. J Biol Chem. 1994;269(51):32435-32440.
60. Metzger H. Transmembrane signaling: the joy of aggregation. J Immunol. 1992;149(5):1477-1487.
61. Harder KW, Quilici C, Naik E, et al. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood. 2004;104(13):3901-3910.
62. Silver KL, Crockford TL, Bouriez-Jones T, Milling S, Lambe T, Cornall RJ. MyD88-dependent autoimmune disease in Lyn-deficient mice. Eur J Immunol. 2007;37(10):2734-2743. (Pubitemid 47578292)
63. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995;83(2):301-311.
64. Jacob A, Cooney D, Tridandapani S, Kelley T, Coggeshall KM. FcgammaRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells. J Biol Chem. 1999;274(19):13704-13710.
65. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol. 2006;91:159-173.
66. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994;94(2):585-591. (Pubitemid 24250987)
67. Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998;112(3):397-402.
68. Lawlor KE, Campbell IK, Metcalf D, et al. Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci U S A. 2004;101(31):11398-11403.
69. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol. 1998;161(7):3639-3644.
70. Kalesnikoff J, Sly LM, Hughes MR, et al. The role of SHIP in cytokine-induced signaling. Rev Physiol Biochem Pharmacol. 2003;149:87-103.